AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

Abstract

BACKGROUND:

Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral drugs is complicated by pharmacokinetic drug-drug interaction.

METHOD:

Pubmed and Google search following the key words tuberculosis, HIV, emtricitabine, tenofovir efavirenz, interaction were used to find relevant information on each drug of the fixed dose combination AtriplaR RESULTS: Information on generic name, trade name, pharmacokinetic parameter, metabolism and the pharmacokinetic interaction with Anti-TB drugs of emtricitabine, tenofovir, and efavirenz was obtained.

CONCLUSION:

Fixed dose combination of emtricitabine/tenofovir/efavirenz (ATRIPLAR) which has been approved by Food and Drug Administration shows promising results as far as safety and efficacy is concerned in TB/HIV co-infection patients, hence can be considered effective and safe antiretroviral drug in TB/HIV management for adult and children above 3 years of age.

• Authors: Hadija H Semvua, Gibson S Kibiki
• Journal: BMC research notes (BMC Res Notes) Vol. 4 Pg. 511 (Nov 24 2011) ISSN: 1756-0500 [Electronic] England
• PMID: 22114934 (Publication Type: Journal Article)